{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:45:08Z","timestamp":1762505108688},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1097\/01.dad.0000199880.71481.0f","type":"journal-article","created":{"date-parts":[[2006,4,19]],"date-time":"2006-04-19T08:04:29Z","timestamp":1145433869000},"page":"168-172","source":"Crossref","is-referenced-by-count":25,"title":["Histologic Patterns of Polyethylene Glycol-liposomal Doxorubicin-related Cutaneous Eruptions"],"prefix":"10.1097","volume":"28","author":[{"given":"Francois M.","family":"Cady","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rayna","family":"Kneuper-Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John S.","family":"Metcalf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-16-20210202","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.2165\/00003495-200262140-00012","article-title":"Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma","volume":"62","author":"Sharpe","year":"2002","journal-title":"Drugs"},{"key":"R2-16-20210202","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1001\/archderm.136.12.1475","article-title":"Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin","volume":"136","author":"Lotem","year":"2000","journal-title":"Arch Dermatol"},{"key":"R3-16-20210202","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/00001813-200308000-00011","article-title":"Radiation recall dermatitis induced by pegylated liposomal doxorubicin","volume":"14","author":"Jimeno","year":"2003","journal-title":"Anticancer Drugs"},{"key":"R4-16-20210202","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1001\/archderm.1989.01670230054008","article-title":"Cutaneous eruptions of lymphocyte recovery","volume":"125","author":"Horn","year":"1989","journal-title":"Arch Dermatol"},{"key":"R5-16-20210202","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/archderm.1993.01680280043007","article-title":"Histologic comparison of autologous graft-versus-host reaction and cutaneous eruption of lymphocyte recovery","volume":"129","author":"Bauer","year":"1993","journal-title":"Arch Dermatol"},{"key":"R6-16-20210202","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jaad.2004.02.019","article-title":"Tissue eosinophils and the perils of using skin biopsy specimens to distinguish between drug hypersensitivity and cutaneous graft-versus-host disease","volume":"51","author":"Marra","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"R7-16-20210202","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1001\/archderm.137.1.75","article-title":"The \u201cdrug vs graft-vs-host disease\u201d conundrum gets tougher, but there is an answer: the challenge to dermatologists","volume":"137","author":"Nghiem","year":"2001","journal-title":"Arch Dermatol"},{"key":"R8-16-20210202","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/archderm.137.1.61","article-title":"Late appearance of acute graft-vs-host disease after suspending or tapering immunosuppressive drugs","volume":"137","author":"Valks","year":"2001","journal-title":"Arch Dermatol"},{"key":"R9-16-20210202","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/ajcp\/112.6.791","article-title":"A reappraisal of the histopathologic criteria for the diagnosis of cutaneous allogeneic acute graft-vs-host disease","volume":"112","author":"Massi","year":"1999","journal-title":"Am J Clin Pathol"},{"key":"R10-16-20210202","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2133.1987.tb05849.x","article-title":"Fixed drug eruption: an immunohistochemical investigation of the acute and healing phase","volume":"116","author":"Hindsen","year":"1987","journal-title":"Br J Dermatol"},{"key":"R11-16-20210202","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1600-0560.1982.tb01060.x","article-title":"Lichen planus and chronic graft-versus-host reaction. In situ identification of immunocompetent cell phenotypes","volume":"9","author":"Gomes","year":"1982","journal-title":"J Cutan Pathol"},{"key":"R12-16-20210202","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1600-0560.1994.tb00277.x","article-title":"Acute cutaneous eruptions after marrow ablation: roses by other names?","volume":"21","author":"Horn","year":"1994","journal-title":"J Cutan Pathol"},{"key":"R13-16-20210202","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1097\/00000478-199709000-00002","article-title":"Value of skin biopsies in assessing prognosis and progression of acute graft-versus-host disease","volume":"21","author":"Kohler","year":"1997","journal-title":"Am J Surg Pathol"},{"key":"R15-16-20210202","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0190-9622(08)80652-4","article-title":"Hydrochlorothiazide-induced lupus erythematosus: a new variant?","volume":"28","author":"Goodrich","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"R16-16-20210202","first-page":"289","article-title":"Lever's Histopathology of the Skin. 8th ed","author":"Horn","year":"1997"},{"key":"R17-16-20210202","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1034\/j.1600-0560.2003.00113.x","article-title":"Intertriginous epidermal dysmaturation from pegylated liposomal doxorubicin","volume":"30","author":"English","year":"2003","journal-title":"J Cutan Pathol"},{"key":"R18-16-20210202","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1034\/j.1600-0560.2002.291002.x","article-title":"Keratinocyte dysplasia: an usual finding after transplantation or chemotherapy","volume":"29","author":"Castano","year":"2002","journal-title":"J Cutan Pathol"},{"key":"R19-16-20210202","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1034\/j.1600-0560.2002.291001.x","article-title":"Chemotherapy and keratinocytes","volume":"22","author":"Henry","year":"2002","journal-title":"J Cutan Pathol"},{"key":"R20-16-20210202","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1034\/j.1600-0560.2002.290304.x","article-title":"Host-vs.-altered host eruptions in patients on liposomal doxorubicin","volume":"29","author":"Skelton","year":"2002","journal-title":"J Cutan Pathol"},{"key":"R21-16-20210202","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1182\/blood.V80.11.2729.2729","article-title":"Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype","volume":"80","author":"Drach","year":"1992","journal-title":"Blood"},{"key":"R22-16-20210202","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2165\/00002018-200124120-00004","article-title":"A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles","volume":"24","author":"Waterhouse","year":"2001","journal-title":"Drug Safety"},{"key":"R23-16-20210202","first-page":"2289","article-title":"Comparison of three approaches to doxorubicin therapy: free doxorubicin, liposomal doxorubicin, and beta-glucuronidase-activated prodrug (HMR 1826)","volume":"20","author":"Woessner","year":"2000","journal-title":"Anticancer Res"},{"issue":"A","key":"R24-16-20210202","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0305-7372(02)80004-4","article-title":"Pegylation: engineering improved pharmaceuticals for enhanced therapy","volume":"28","author":"Molineux","year":"2002","journal-title":"Cancer Treat Rev"},{"key":"R25-16-20210202","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1081\/CNV-100103136","article-title":"Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy","volume":"19","author":"Gabizon","year":"2001","journal-title":"Cancer Invest"},{"issue":"A","key":"R26-16-20210202","first-page":"13","article-title":"Novel effects with polyethylene glycol modified pharmaceuticals","volume":"28","author":"Yowell","year":"2002","journal-title":"Cancer Treat Rev"},{"key":"R27-16-20210202","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1158\/0008-5472.CAN-03-0576","article-title":"Radiation improves the distribution and uptake of liposomal doxorubicin (caelyx) in human osteosarcoma xenografts","volume":"64","author":"Davies","year":"2004","journal-title":"Cancer Res"},{"key":"R28-16-20210202","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1148\/radiol.2352031856","article-title":"Combination radiofrequency ablation with intratumoral liposomal doxorubicin: effect on drug accumulation and coagulation in multiple tissues and tumor types in animals","volume":"235","author":"Ahmed","year":"2005","journal-title":"Radiology"},{"key":"R29-16-20210202","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2214\/ajr.179.1.1790093","article-title":"Radiofrequency ablation of hepatic tumors: increased tumor destruction with adjuvant liposomal doxorubicin therapy","volume":"179","author":"Goldberg","year":"2002","journal-title":"Am J Roentgenol"},{"key":"R30-16-20210202","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1067\/mjd.2000.101589","article-title":"A case of cutaneous reaction to chemotherapeutic agents showing epidermal dysmaturation","volume":"43","author":"Chun","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"R31-16-20210202","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1600-0560.1985.tb01613.x","article-title":"Cutaneous busulfan effect in patients receiving bone marrow transplantation","volume":"12","author":"Hymes","year":"1985","journal-title":"J Cutan Pathol"},{"key":"R32-16-20210202","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/S0190-9622(09)80082-0","article-title":"Bowenoid change in association with graft-versus-host disease: a cyclosporine toxicity?","volume":"31","author":"Bulengo-Ransby","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"R33-16-20210202","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1600-0560.1987.tb01532.x","article-title":"Cutaneous pathology following etoposide therapy","volume":"14","author":"Yokel","year":"1987","journal-title":"J Cutan Pathol"},{"key":"R34-16-20210202","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/archderm.1995.01690140086015","article-title":"Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent","volume":"131","author":"Zimmermann","year":"1995","journal-title":"Arch Dermatol"},{"key":"R35-16-20210202","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/archderm.1989.01670160072011","article-title":"Observations and proposed mechanism of thiotepa-induced hyperpigmentation","volume":"125","author":"Horn","year":"1989","journal-title":"Arch Dermatol"}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.dad.0000199880.71481.0f","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T20:24:46Z","timestamp":1620937486000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000372-200604000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.dad.0000199880.71481.0f","relation":{},"ISSN":["0193-1091"],"issn-type":[{"value":"0193-1091","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}